Comparative Pharmacology
Head-to-head clinical analysis: AVANDAMET versus PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVANDAMET versus PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE.
AVANDAMET vs PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVANDAMET combines rosiglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPARγ), and metformin, a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Pioglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor-gamma (PPAR-γ), increasing insulin sensitivity in adipose tissue, skeletal muscle, and liver. Metformin is a biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Oral, initial dose of rosiglitazone 4 mg/metformin 500 mg twice daily or rosiglitazone 2 mg/metformin 500 mg twice daily; maximum recommended dose rosiglitazone 8 mg/metformin 2000 mg per day.
Initial: 15 mg pioglitazone/500 mg metformin twice daily or 30 mg pioglitazone/500 mg metformin once daily. Titrate gradually based on glycemic response. Maximum: 45 mg pioglitazone/2000 mg metformin per day in divided doses.
None Documented
None Documented
Rosiglitazone: 3-4 hours (terminal); metformin: 6.2 hours (terminal). No accumulation with normal renal function.
Metformin: 6.2 hours (increased in renal impairment). Pioglitazone: 3-7 hours (parent), 16-24 hours (active metabolites), requiring once-daily dosing.
Renal (90-95% as unchanged drug for rosiglitazone; metformin is 90% renally eliminated unchanged). Biliary/fecal: minor (<5% for both).
Metformin: 90% renal (unchanged), 10% fecal. Pioglitazone: 60-70% renal (metabolites), 20-30% fecal.
Category C
Category A/B
Thiazolidinedione and Biguanide Combination
Thiazolidinedione